🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

PREdiction of succeSSful weanING From Continuous Renal Replacement Theraphy: the Possible Role of Delta C-cistatin

Recruitingn/aAges 18 Years - anyAllIRCCS Azienda Ospedaliero-Universitaria di Bologna
NCT06714214 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to know if, in patients with acute kidney injury, naive for renal injurie, admitted to different ICUs, the change in plasma concentration of c-cistatin, between initiation and discontinuation of CRRT, is a predictive finding to optimize the withdrawal time of renal support

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * age ≥ 18 years; * diagnosis of acute kidney injury (defined according to KDIGO 2012 criteria) * need for support with CRRT according to the indications of the nephrologist consultants and Clinical Practice * Obtaining informed consent Exclusion Criteria: * CRRT already ongoing (in another department not participating in the study) at the time of transfer/admission to intensive care; * need for RRT (any type and modality) in the 14 days prior to enrolment; * diagnosis of AKD/CKD/ESRF on admission; * Discontinuation of CRRT under conditions that do not comply with the criteria established by the study; * Need for CRRT not associated with AKI condition (e.g. elimination of toxicants); * pregnant women; * presence of known thyreopathy * Continuous use of corticosteroids * patient with known neoplastic disease.
💊

What it tests

  • Not listed
📍

Where

2 sites
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Anestesia e Terapia Intensiva nelle emergenze locali, regionali e nazionale e nella chirurgia addominale maggiore
Bologna, Italy
IRCCS Azienda Ospedaliero-Universitaria di Bologna -Anestesiologia e terapia intensiva polivalente
Bologna, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy